SCHEMBL4125052

SCHEMBL4125052

CCCC(C(=O)O)c1ccc(NC2=NC(=O)C(=Cc3cc(OCC)c4ccccc4c3OCC)S2)cc1F

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.34
AURKA O14965 1/20 0.33
KMT2A Q03164 6/20 0.33
MEN1 O00255 5/20 0.33
FABP4 P15090 1/20 0.32
MAPT P10636 3/20 0.32
KDM4E B2RXH2 2/20 0.32
CYP1A2 P05177 1/20 0.32
HPGD P15428 1/20 0.32
CYP2C19 P33261 1/20 0.32
RXFP1 Q9HBX9 1/20 0.32
CISD1 Q9NZ45 1/20 0.32
CHEK1 O14757 1/20 0.31
DAPK3 O43293 1/20 0.31
PRKD3 O94806 1/20 0.31
PIM1 P11309 1/20 0.31
MAPK8 P45983 1/20 0.31
CSNK1A1 P48729 1/20 0.31
CDK8 P49336 1/20 0.31
CLK2 P49760 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4125049 1.00 TDP1 (0.34) TDP1AURKAKMT2AMEN1FABP4
SCHEMBL4141046 0.90 TDP1 (0.36) TDP1AURKAKMT2AMEN1FABP4
SCHEMBL4141047 0.90 TDP1 (0.36) TDP1AURKAKMT2AMEN1FABP4
SCHEMBL4134464 0.78 PTP4A3 (0.36) TDP1KMT2AMEN1MAPTKDM4E
SCHEMBL4134460 0.78 PTP4A3 (0.36) TDP1KMT2AMEN1MAPTKDM4E
SCHEMBL4141062 0.78 PTPN1 (0.42) KMT2AMEN1MAPTCYP1A2HPGD
SCHEMBL4141057 0.78 PTPN1 (0.42) KMT2AMEN1MAPTCYP1A2HPGD
SCHEMBL4127235 0.76 KMT2A (0.39) TDP1KMT2AMEN1MAPTKDM4E
SCHEMBL4127232 0.76 KMT2A (0.39) TDP1KMT2AMEN1MAPTKDM4E
SCHEMBL4134027 0.74 CHEK1 (0.32) TDP1KMT2AMEN1HPGDCHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US claimed
CN-101268060-A Thiazolinone and oxazolinone compounds and application thereof as PTP1B inhibitor TORRENT PHARMACEUTICALS LTD (IN) 2008-09-17 CN claimed
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US disclosed
CN-101268060-A Thiazolinone and oxazolinone compounds and application thereof as PTP1B inhibitor TORRENT PHARMACEUTICALS LTD (IN) 2008-09-17 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors PTPRF, PTPA, PTPRJ TDP1 1151/4885AURKA 3533/4885KMT2A 2895/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.